8-K Announcements
6Material company update
Apr 8, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Mar 2, 2026·SEC
MacroGenics, Inc.(MGNX)Earnings, Financials & Key Ratios
MGNX•NASDAQ
$3.15
$199M mkt cap·Price updated May 6, 2026
AboutMacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Show more
- Revenue$150M+0.8%
- EBITDA-$73M+29.3%
- Net Income-$75M-11.4%
- EPS (Diluted)-1.18-10.3%
- EBITDA Margin-48.72%+29.9%
- Operating Margin-48.72%+34.6%
- Net Margin-49.91%-10.6%
- ROE-86.95%-74.4%
- ROIC-1879.28%-538.0%
- Debt/Equity0.66+104.9%
MGNX Key Insights
MacroGenics, Inc. (MGNX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MGNX Price & Volume
MacroGenics, Inc. (MGNX) stock price & volume — 10-year historical chart
Loading chart...
MGNX Growth Metrics
MacroGenics, Inc. (MGNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.01%
5 Years8.87%
3 Years-0.12%
TTM0.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-9.26%
Return on Capital
10 Years-46.47%
5 Years-54.19%
3 Years-51.22%
Last Year-34.7%
MGNX Recent Earnings
MacroGenics, Inc. (MGNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Mar 9, 2026EPS
$0.22
Est $0.42
+47.6%
Revenue
$41M
Est $35M
+19.2%
Q4 2025
Nov 12, 2025EPS
$0.27
Est $0.48
+156.3%
Revenue
$73M
Est $28M
+161.9%
Q3 2025
Aug 14, 2025EPS
$0.57
Est $0.59
+3.4%
Revenue
$22M
Est $24M
-8.9%
Q2 2025
May 13, 2025EPS
$0.65
Est $0.61
-6.6%
Revenue
$13M
Est $12M
+12.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 9, 2026 | $0.22vs $0.42+47.6% | $41Mvs $35M+19.2% |
| Q4 2025 | Nov 12, 2025 | $0.27vs $0.48+156.3% | $73Mvs $28M+161.9% |
| Q3 2025 | Aug 14, 2025 | $0.57vs $0.59+3.4% | $22Mvs $24M-8.9% |
| Q2 2025 | May 13, 2025 | $0.65vs $0.61-6.6% | $13Mvs $12M+12.1% |
Based on last 12 quarters of dataView full earnings history →
MGNX Peer Comparison
MacroGenics, Inc. (MGNX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 FATE | 272.25M | 2.36 | -2.05 | -51.24% | -20.51% | -65.79% | 0.38 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 XNCR | 923.55M | 12.85 | -10.36 | -100% | -7.23% | 0.05 | ||
 AGEN | 147.29M | 4.17 | -1226.47 | 10.37% | 0.1% | |||
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 ZYME | 1.98B | 26.68 | -24.70 | 38.87% | -76.56% | -26% | 0.07 | |
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% |
Compare MGNX vs Peers
MacroGenics, Inc. (MGNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MGNX Income Statement
MacroGenics, Inc. (MGNX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 155.52M | 60.12M | 62.02M | 97.76M | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Revenue Growth % | 79.62% | -61.34% | 3.17% | 57.62% | -22.63% | 98.32% | -61.88% | 159.37% | 0.78% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 2.65M | 7.38M | 8.22M | 12.3M | 0 |
| COGS % of Revenue | - | - | - | - | 3.5% | 4.92% | 14.38% | 8.29% | - |
| Gross Profit | 155.52M▲ 0% | 60.12M▼ 61.3% | 62.02M▲ 3.2% | 97.76M▲ 57.6% | 72.99M▼ 25.3% | 142.63M▲ 95.4% | 48.97M▼ 65.7% | 136.04M▲ 177.8% | 0▼ 100.0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 96.5% | 95.08% | 85.62% | 91.71% | - |
| Gross Profit Growth % | 79.62% | -61.34% | 3.17% | 57.62% | -25.34% | 95.41% | -65.67% | 177.8% | -100% |
| Operating Expenses | 177.66M | 231.33M | 239.21M | 228.82M | 275.79M | 264.05M | 217.22M | 246.62M | 186.33M |
| OpEx % of Revenue | 114.24% | 384.77% | 385.67% | 234.06% | 364.59% | 176.01% | 379.79% | 166.25% | 124.64% |
| Selling, General & Admin | 32.65M | 40.5M | 46.06M | 42.74M | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| SG&A % of Revenue | 21% | 67.36% | 74.27% | 43.72% | 83.3% | 39.29% | 91.25% | 47.89% | 26.19% |
| Research & Development | 147.23M | 190.83M | 195.31M | 193.2M | 214.58M | 207.03M | 166.58M | 177.19M | 147.17M |
| R&D % of Revenue | 94.67% | 317.4% | 314.89% | 197.62% | 283.67% | 138% | 291.26% | 119.45% | 98.44% |
| Other Operating Expenses | 2.52M | -247K | -2.16M | -7.12M | -1.8M | -1.92M | -1.56M | -1.62M | 0 |
| Operating Income | -22.14M▲ 0% | -171.21M▼ 673.2% | -177.19M▼ 3.5% | -131.06M▲ 26.0% | -202.79M▼ 54.7% | -121.42M▲ 40.1% | -168.24M▼ 38.6% | -110.58M▲ 34.3% | -72.84M▲ 34.1% |
| Operating Margin % | -14.24% | -284.77% | -285.67% | -134.06% | -268.09% | -80.94% | -294.17% | -74.54% | -48.72% |
| Operating Income Growth % | 63.12% | -673.18% | -3.49% | 26.03% | -54.73% | 40.13% | -38.57% | 34.28% | 34.13% |
| EBITDA | -14.91M | -162.01M | -164.88M | -119.1M | -191.54M | -109.55M | -158.6M | -103.04M | -72.84M |
| EBITDA Margin % | -9.59% | -269.47% | -265.83% | -121.83% | -253.21% | -73.03% | -277.3% | -69.46% | -48.72% |
| EBITDA Growth % | 71.55% | -986.2% | -1.77% | 27.76% | -60.82% | 42.8% | -44.77% | 35.03% | 29.31% |
| D&A (Non-Cash Add-back) | 7.23M | 9.2M | 12.31M | 11.96M | 11.26M | 11.87M | 9.64M | 7.54M | 0 |
| EBIT | -22.14M | -171.21M | -177.19M | -131.06M | -202.12M | -119.76M | -7.63M | -64.91M | 0 |
| Net Interest Income | 0 | 0 | 3.4M | 800K | 680K | 1.7M | 8.26M | 8.31M | 0 |
| Interest Income | 0 | 0 | 3.4M | 800K | 680K | 1.7M | 9.69M | 9.42M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 1.43M | 1.11M | -8.51M |
| Other Income/Expense | 2.52M | -247K | 25.37M | 1.32M | 680K | 1.66M | 159.19M | 44.56M | -2.45M |
| Pretax Income | -19.63M▲ 0% | -171.45M▼ 773.6% | -151.81M▲ 11.5% | -129.74M▲ 14.5% | -202.12M▼ 55.8% | -119.76M▲ 40.7% | -9.06M▲ 92.4% | -66.02M▼ 628.9% | -75.29M▼ 14.0% |
| Pretax Margin % | -12.62% | -285.18% | -244.76% | -132.71% | -267.2% | -79.83% | -15.84% | -44.51% | -50.36% |
| Income Tax | 0 | -247K | 0 | 0 | 0 | 0 | 0 | 944K | -672K |
| Effective Tax Rate % | 0% | 0.14% | 0% | 0% | 0% | 0% | 0% | -1.43% | 0.89% |
| Net Income | -19.63M▲ 0% | -171.45M▼ 773.6% | -151.81M▲ 11.5% | -129.74M▲ 14.5% | -202.12M▼ 55.8% | -119.76M▲ 40.7% | -9.06M▲ 92.4% | -66.97M▼ 639.3% | -74.62M▼ 11.4% |
| Net Margin % | -12.62% | -285.18% | -244.76% | -132.71% | -267.2% | -79.83% | -15.84% | -45.14% | -49.91% |
| Net Income Growth % | 66.47% | -773.6% | 11.46% | 14.54% | -55.79% | 40.75% | 92.44% | -639.3% | -11.43% |
| Net Income (Continuing) | -19.63M | -171.45M | -151.81M | -129.74M | -202.12M | -119.76M | -9.06M | -66.97M | -74.62M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.54▲ 0% | -4.19▼ 675.9% | -3.16▲ 24.6% | -2.25▲ 28.8% | -3.18▼ 41.3% | -1.95▲ 38.7% | -0.15▲ 92.3% | -1.07▼ 613.3% | -1.18▼ 10.3% |
| EPS Growth % | 68.05% | -675.93% | 24.58% | 28.8% | -41.33% | 38.68% | 92.31% | -613.33% | -10.28% |
| EPS (Basic) | -0.54 | -4.19 | -3.16 | -2.25 | -3.18 | -1.95 | -0.15 | -1.07 | -1.18 |
| Diluted Shares Outstanding | 36.1M | 40.93M | 48.08M | 52.44M | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
| Basic Shares Outstanding | 36.1M | 40.93M | 48.08M | 52.44M | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MGNX Balance Sheet
MacroGenics, Inc. (MGNX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 322.3M | 269.12M | 239.78M | 312.59M | 279.56M | 222.18M | 251.34M | 217.49M | 219.94M |
| Cash & Short-Term Investments | 305.12M | 232.86M | 215.76M | 272.53M | 243.62M | 154.35M | 229.81M | 201.67M | 189.91M |
| Cash Only | 211.73M | 220.13M | 126.47M | 181.13M | 123.47M | 108.88M | 100.96M | 182.84M | 57.22M |
| Short-Term Investments | 93.39M | 12.73M | 89.28M | 91.4M | 120.15M | 45.46M | 128.85M | 18.83M | 132.7M |
| Accounts Receivable | 13.64M | 29.58M | 12.74M | 23.08M | 10.39M | 56.22M | 10.37M | 4.31M | 13.37M |
| Days Sales Outstanding | 32.02 | 179.6 | 75 | 86.17 | 50.12 | 136.79 | 66.16 | 10.6 | 32.65 |
| Inventory | 0 | 0 | 0 | 0 | 4.39M | 1.45M | 1.22M | 0 | 7.91M |
| Days Inventory Outstanding | - | - | - | - | 604.16 | 71.72 | 54.2 | - | - |
| Other Current Assets | 383K | 0 | 0 | 0 | 0 | 10.16M | 9.95M | 11.51M | 8.74M |
| Total Non-Current Assets | 51.59M | 63.01M | 72.72M | 66.15M | 55.69M | 67.33M | 47.08M | 53.06M | 36.91M |
| Property, Plant & Equipment | 49.98M | 56.71M | 68.41M | 61.52M | 54.29M | 56.91M | 45.69M | 42.61M | 35.52M |
| Fixed Asset Turnover | 3.11x | 1.06x | 0.91x | 1.59x | 1.39x | 2.64x | 1.25x | 3.48x | 4.21x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.6M | 6.29M | 4.3M | 4.62M | 1.4M | 1.38M | 1.39M | 10.46M | 1.39M |
| Total Assets | 373.88M▲ 0% | 332.13M▼ 11.2% | 312.5M▼ 5.9% | 378.74M▲ 21.2% | 335.25M▼ 11.5% | 289.51M▼ 13.6% | 298.42M▲ 3.1% | 261.65M▼ 12.3% | 256.85M▼ 1.8% |
| Asset Turnover | 0.42x | 0.18x | 0.20x | 0.26x | 0.23x | 0.52x | 0.19x | 0.57x | 0.58x |
| Asset Growth % | 20.12% | -11.17% | -5.91% | 21.2% | -11.48% | -13.64% | 3.08% | -12.32% | -1.84% |
| Total Current Liabilities | 49.76M | 59.94M | 45.17M | 50.67M | 74.58M | 48.61M | 56.11M | 55.53M | 43.12M |
| Accounts Payable | 2.45M | 4M | 4.31M | 8.03M | 15.5M | 4.9M | 6.44M | 5.01M | 4.79M |
| Days Payables Outstanding | - | - | - | - | 2.13K | 242.16 | 286.02 | 148.77 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 4.73M | 0 | 0 | 5.18M |
| Deferred Revenue (Current) | 7.2M | 21.72M | 0 | 0 | 0 | 9.99M | 21.65M | 16.32M | 10.92M |
| Other Current Liabilities | 1.52M | 1.02M | 10.7M | 4.46M | 20.65M | 29M | 0 | 0 | 27.02M |
| Current Ratio | 6.48x | 4.49x | 5.31x | 6.17x | 3.75x | 4.57x | 4.48x | 3.92x | 5.10x |
| Quick Ratio | 6.48x | 4.49x | 5.31x | 6.17x | 3.69x | 4.54x | 4.46x | 3.92x | 4.92x |
| Cash Conversion Cycle | - | - | - | - | -1.48K | -33.65 | -165.66 | - | - |
| Total Non-Current Liabilities | 24.89M | 29.31M | 36.71M | 32.19M | 21.05M | 98.89M | 89.7M | 98.97M | 158.14M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31.59M |
| Capital Lease Obligations | 0 | 0 | 27.55M | 25.26M | 20.79M | 30.11M | 30.2M | 32.6M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 9.04M | 0 | 8.9M | 0 |
| Other Non-Current Liabilities | 4.05M | 10.31M | 9.15M | 6.93M | 258K | 258K | 258K | 1.97M | 126.56M |
| Total Liabilities | 74.64M | 89.25M | 81.87M | 82.86M | 95.63M | 147.5M | 145.81M | 145.6M | 201.25M |
| Total Debt | 298K | 0 | 30.57M | 29.25M | 25.47M | 34.83M | 33.97M | 37.46M | 36.76M |
| Net Debt | -211.43M | -220.13M | -95.9M | -151.88M | -98M | -74.05M | -66.98M | -145.38M | -20.45M |
| Debt / Equity | 0.00x | - | 0.13x | 0.10x | 0.11x | 0.25x | 0.22x | 0.32x | 0.66x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -117.65x | -99.17x | - |
| Total Equity | 299.24M▲ 0% | 242.88M▼ 18.8% | 230.63M▼ 5.0% | 295.88M▲ 28.3% | 239.62M▼ 19.0% | 142.01M▼ 40.7% | 152.61M▲ 7.5% | 116.06M▼ 24.0% | 55.59M▼ 52.1% |
| Equity Growth % | 11.34% | -18.83% | -5.04% | 28.29% | -19.02% | -40.73% | 7.46% | -23.95% | -52.1% |
| Book Value per Share | 8.29 | 5.93 | 4.80 | 5.64 | 4.00 | 2.31 | 2.46 | 1.85 | 0.88 |
| Total Shareholders' Equity | 299.24M | 242.88M | 230.63M | 295.88M | 239.62M | 142.01M | 152.61M | 116.06M | 55.59M |
| Common Stock | 369K | 424K | 490K | 562K | 613K | 617K | 621K | 628K | 633K |
| Retained Earnings | -312.34M | -490.27M | -642.08M | -771.82M | -973.94M | -1.09B | -1.1B | -1.17B | -1.24B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -61K | -3K | 16K | -7K | -61K | -5K | -6K | 4K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MGNX Cash Flow Statement
MacroGenics, Inc. (MGNX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 14.4M | -153.23M | -134.27M | -111.9M | -143.83M | -86.96M | -78.2M | -68.37M | -81.04M |
| Operating CF Margin % | 9.26% | -254.88% | -216.48% | -114.46% | -190.14% | -57.97% | -136.74% | -46.09% | -54.21% |
| Operating CF Growth % | 132.98% | -1163.76% | 12.38% | 16.66% | -28.54% | 39.54% | 10.07% | 12.57% | -18.53% |
| Net Income | -19.63M | -171.45M | -151.81M | -129.74M | -202.12M | -119.76M | -9.06M | -66.97M | -74.62M |
| Depreciation & Amortization | 7.23M | 8.28M | 10.85M | 11.96M | 11.26M | 11.87M | 9.64M | 7.54M | 5.52M |
| Stock-Based Compensation | 14.74M | 16.52M | 19.57M | 20.68M | 23.13M | 20.44M | 18.37M | 29.44M | 14.29M |
| Deferred Taxes | 0 | 0 | -25.09M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 41.62M | 48.39M | 25.09M | -260K | 6.33M | 6.63M | -150.48M | -39.78M | -26.23M |
| Working Capital Changes | 12.06M | -6.58M | -12.88M | -14.53M | 17.57M | -6.13M | 53.32M | 1.39M | 0 |
| Change in Receivables | -10.88M | -15.94M | 16.84M | -10.34M | 12.7M | -45.84M | 45.85M | 6.06M | -9.06M |
| Change in Inventory | 11.83M | -4.63M | -9.63M | 0 | -6.42M | 55K | 230K | -2.19M | -7.91M |
| Change in Payables | -1.54M | 1.55M | 787K | 3.72M | 7.13M | -10.86M | 1.28M | -1.53M | -280K |
| Cash from Investing | 77.88M | 56.64M | -79.36M | -7.79M | -36.61M | 70.72M | -80.08M | 149.3M | -114.1M |
| Capital Expenditures | -29.4M | -24.95M | -4.29M | -5.91M | -6.2M | -3.62M | -1.76M | -3.71M | -1.91M |
| CapEx % of Revenue | 18.91% | 41.51% | 6.92% | 6.04% | 8.2% | 2.42% | 3.08% | 2.5% | 1.28% |
| Acquisitions | 0 | 0 | 75.07M | 0 | 0 | 0 | 64K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 107.28M | 81.6M | -75.07M | 0 | 0 | 0 | 0 | 40.16M | 11K |
| Cash from Financing | 35.35M | 104.99M | 119.97M | 174.34M | 122.78M | 1.66M | 150.36M | 960K | 69.51M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -157K | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -40K | -260K | 0 | -2.01M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.14M | 1.99M | 1.31M | 3.89M | 4.96M | 574K | 149.35M | 960K | 69.51M |
| Net Change in Cash | 127.63M▲ 0% | 8.4M▼ 93.4% | -93.66M▼ 1214.8% | 54.66M▲ 158.4% | -57.66M▼ 205.5% | -14.59M▲ 74.7% | -7.93M▲ 45.6% | 81.88M▲ 1132.8% | -125.62M▼ 253.4% |
| Free Cash Flow | -15M▲ 0% | -178.19M▼ 1088.1% | -138.56M▲ 22.2% | -117.8M▲ 15.0% | -150.03M▼ 27.4% | -90.58M▲ 39.6% | -79.97M▲ 11.7% | -72.08M▲ 9.9% | -82.95M▼ 15.1% |
| FCF Margin % | -9.64% | -296.38% | -223.4% | -120.5% | -198.34% | -60.38% | -139.82% | -48.59% | -55.49% |
| FCF Growth % | 72.76% | -1088.08% | 22.24% | 14.98% | -27.36% | 39.62% | 11.72% | 9.87% | -15.09% |
| FCF per Share | -0.42 | -4.35 | -2.88 | -2.25 | -2.50 | -1.47 | -1.29 | -1.15 | -1.31 |
| FCF Conversion (FCF/Net Income) | -0.73x | 0.89x | 0.88x | 0.86x | 0.71x | 0.73x | 8.63x | 1.02x | 1.09x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 944K | 0 |
MGNX Key Ratios
MacroGenics, Inc. (MGNX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -20.11% | -6.91% | -63.25% | -64.12% | -49.28% | -75.49% | -62.76% | -6.15% | -49.85% | -86.95% |
| Return on Invested Capital (ROIC) | -29.2% | -12.11% | -232.28% | -168.77% | -70.53% | -106.5% | -86.9% | -164.31% | -294.58% | -1879.28% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 96.5% | 95.08% | 85.62% | 91.71% | - |
| Net Margin | -67.6% | -12.62% | -285.18% | -244.76% | -132.71% | -267.2% | -79.83% | -15.84% | -45.14% | -49.91% |
| Debt / Equity | 0.01x | 0.00x | - | 0.13x | 0.10x | 0.11x | 0.25x | 0.22x | 0.32x | 0.66x |
| Interest Coverage | - | - | - | - | - | - | - | -117.65x | -99.17x | - |
| FCF Conversion | 0.75x | -0.73x | 0.89x | 0.88x | 0.86x | 0.71x | 0.73x | 8.63x | 1.02x | 1.09x |
| Revenue Growth | -14.15% | 79.62% | -61.34% | 3.17% | 57.62% | -22.63% | 98.32% | -61.88% | 159.37% | 0.78% |
MGNX SEC Filings & Documents
MacroGenics, Inc. (MGNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
MGNX Frequently Asked Questions
MacroGenics, Inc. (MGNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MacroGenics, Inc. (MGNX) reported $149.5M in revenue for fiscal year 2025. This represents a 218% increase from $47.1M in 2011.
MacroGenics, Inc. (MGNX) grew revenue by 0.8% over the past year. Growth has been modest.
MacroGenics, Inc. (MGNX) reported a net loss of $74.6M for fiscal year 2025.
Dividend & Returns
MacroGenics, Inc. (MGNX) has a return on equity (ROE) of -86.9%. Negative ROE indicates the company is unprofitable.
MacroGenics, Inc. (MGNX) had negative free cash flow of $83.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More MGNX
MacroGenics, Inc. (MGNX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates